Due to the well documented role in excito-toxicity, the potential of the NMDA receptor
complex as a therapeutic site has been viewed cautiously. Treatment of AD patients with a …

Cortical inhibitory neurotransmitters, neuropeptides, dopamine and noradrenaline are
probably either not selectively or not critically affected in AD. It is, however, likely that a key …

Due to the well documented role in excito-toxicity, the potential of the NMDA receptor
complex as a therapeutic site has been viewed cautiously. Treatment of AD patients with a …

The concept of Alzheimer's disease as a treatable condition has a short history but already
some would claim that we stand on the threshold of a new age in dementia care withthe …

Many neuropsychiatric disorders affect memory. Brain regions important in the
neuroanatomic substrate of memory include the hippocampus, and sections of the frontal …

Drug development for Alzheimer's disease has so far had little success, possibly due to
failure to correct abnormalities of neurones other than the corticopetal. Most enquiries …

Pathologic changes in the brain that are characteristic of Alzheimer's disease (AD) appear to
begin many decades before the onset of clinical It is not until relatively late in life, when, in …

Publisher Summary The study of specific neurotransmitter systems is a hot topic in
neurobiology. Thus, various neurotransmitter substitution therapies are proposed for …

In earlier publications, I posited that Alzheimer's disease is but a runaway autoimmune
disease as we age and that the compromised integrity of the blood-brain barrier is a …

The etiology of Alzheimer's disease (AD) is still unknown, and a definitive diagnosis of the
disease can be determined only at autopsy or by brain biopsy. AD can be characterized by …